DiaMedica Therapeutics Inc (NASDAQ:DMAC) – Research analysts at Dougherty & Co issued their Q4 2019 earnings per share (EPS) estimates for shares of DiaMedica Therapeutics in a research report issued to clients and investors on Friday, November 15th. Dougherty & Co analyst K. Bauser anticipates that the company will post earnings per share of ($0.25) for the quarter.
DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01).
NASDAQ DMAC opened at $3.75 on Monday. The company has a current ratio of 8.97, a quick ratio of 12.96 and a debt-to-equity ratio of 0.01. DiaMedica Therapeutics has a 52 week low of $1.70 and a 52 week high of $5.93. The firm has a 50 day moving average of $2.66 and a two-hundred day moving average of $3.14.
A number of hedge funds and other institutional investors have recently bought and sold shares of DMAC. Commonwealth Equity Services LLC acquired a new position in DiaMedica Therapeutics during the 3rd quarter worth approximately $27,000. BlackRock Inc. grew its holdings in DiaMedica Therapeutics by 159.7% during the 2nd quarter. BlackRock Inc. now owns 27,075 shares of the company’s stock worth $134,000 after acquiring an additional 16,651 shares in the last quarter. Vanguard Group Inc. acquired a new position in shares of DiaMedica Therapeutics in the 2nd quarter valued at $170,000. Eidelman Virant Capital acquired a new position in shares of DiaMedica Therapeutics in the 2nd quarter valued at $173,000. Finally, Worth Venture Partners LLC boosted its holdings in shares of DiaMedica Therapeutics by 10.6% in the 2nd quarter. Worth Venture Partners LLC now owns 132,514 shares of the company’s stock valued at $657,000 after buying an additional 12,651 shares in the last quarter. Institutional investors own 10.73% of the company’s stock.
DiaMedica Therapeutics Company Profile
DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.
Further Reading: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.